← All trials
NCT01195298
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2010
- Primary completion
- Aug 1, 2011
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 88
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- South Eastern European Research Oncology GroupLead sponsor
- Medical University of BialystokOverall official - principal investigator
- Petz, Aladar Korhaz, Onkoradiologiai Osztaly, Gyor, HungaryOverall official - principal investigator
- Cancer Centre and Institute of Oncology WarsawOverall official - principal investigator
- Szent László HospitalOverall official - principal investigator
- University of ZagrebOverall official - principal investigator
- RocheCollaborator
- University of SplitOverall official - principal investigator
- Clinical Center of MontenegroOverall official - principal investigator
- Masaryk UniversityOverall official - principal investigator
- Prof. Dr. I. Chiricuta Institute of OncologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.